ADTX ADiTx Therapeutics Inc.

4.6
-0.43  -9%
Previous Close 5.03
Open 4.75
52 Week Low 2.83
52 Week High 9.58
Market Cap $29,429,760
Shares 6,400,000
Float 4,577,475
Enterprise Value $38,634,634
Volume 278,784
Av. Daily Volume 0
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
ADi
Psoriasis
Phase 1/2
Phase 1/2
Phase 1/2 trial planned.

Latest News

  1. Company Plans to file for an Emergency Use Authorization (EUA) and 510(k) Application in the Current Quarter (Q3, 2020)

    Loma Linda, CA, Aug. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Aditxt Therapeutics, Inc. (Aditxt) (the "Company") (NASDAQ:ADTX), a life sciences company developing technologies focused on improving the health of the immune system through immune monitoring and reprogramming, today introduced AditxtScore™ for COVID-19 to be used in detecting antibodies against SARS-CoV-2 antigens, as validated in studies performed by Stanford Blood Center, headquartered in Palo Alto, California.

    AditxtScore™ for COVID-19 is a double-multiplex assay that can be used to detect and differentiate various antibody isotypes (IgG, IgM…

    Company Plans to file for an Emergency Use Authorization (EUA) and 510(k) Application in the Current Quarter (Q3, 2020)

    Loma Linda, CA, Aug. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Aditxt Therapeutics, Inc. (Aditxt) (the "Company") (NASDAQ:ADTX), a life sciences company developing technologies focused on improving the health of the immune system through immune monitoring and reprogramming, today introduced AditxtScore™ for COVID-19 to be used in detecting antibodies against SARS-CoV-2 antigens, as validated in studies performed by Stanford Blood Center, headquartered in Palo Alto, California.

    AditxtScore™ for COVID-19 is a double-multiplex assay that can be used to detect and differentiate various antibody isotypes (IgG, IgM, IgA) against multiple SARS-CoV-2 antigens (e.g. RBD, S1, NP) simultaneously in a single reaction. Currently, one of the most widely used platforms, ELISA, can only detect one antibody isotype against one antigen at a time. AditxtScore™ for COVID-19 increases the resolution of results obtained for each antibody isotype thereby enhancing sensitivity for monitoring changes in these values over time. Due to the enhanced specificity and sensitivity of this comprehensive antibody profiling system, false positive and false negative results have proven to be significantly reduced when testing for the antibodies produced to SARS-CoV-2, thereby expanding its utility beyond a tool used in epidemiology. Therefore, and importantly, AditxtScore™ for COVID-19 can serve as a valuable tool to evaluate immune responses to SARS-CoV-2 vaccines in clinical settings.

    Aditxt plans to file for an Emergency Use Authorization (EUA) followed by a 510(K) application with the U.S. Food and Drug Administration by the end of the current quarter (Q3, 2020). Additionally, Aditxt is planning its operational capabilities in anticipation of beginning pilot programs utilizing AditxtScore™ for COVID-19 in Q4, 2020, with the goal of making AditxtScore™ commercially available starting in Q1, 2021.

    Harpreet Sandhu, Chief Executive Officer of Stanford Blood Center (SBC), commented, "The AditxtScore™ for COVID-19 has the potential to be a game changer for our industry. AditxtScore™ for COVID-19 is a multiplexed platform that has shown tremendous speed and accuracy, which is extremely critical for meeting the ongoing COVID-19 challenge. My team and I look forward to further exploring this platform and potentially collaborating with Aditxt on future projects."

    Amro Albanna, Co-founder and Chief Executive Officer of Aditxt, added, "Our vision for AditxtScore™ is to transform immune diagnosis from reactive testing to proactive monitoring.  The AditxtScore™ platform is a transformative approach for monitoring and predicting immune responses by providing meaningful information in a timely manner.  Now that we have successfully completed the validation study of the first product, our goal is to quickly secure the necessary regulatory requirements to deploy AditxtScore™ for COVID-19 and contribute to addressing the current national and global pandemic we are all facing. The AditxtScore™ platform is built to evaluate the status of the immune system and the COVID-19 application is only the first product to demonstrate its potential. We are actively working to develop AditxtScore™ for other applications, including predicting immune responses to vaccination and early detection of Type I Diabetes, among others."

    About Stanford Blood Center

    Stanford Blood Center (SBC) is an independent, community blood center that supplies blood products and testing services to multiple Bay Area hospitals and is a recognized leader in the fields of transfusion and transplantation medicine. SBC was created at the Stanford University School of Medicine in 1978 to meet the complex transfusion and transplant needs of Stanford Health Care and Lucile Packard Children's Hospital Stanford, as well as provide clinical trial services and specialized blood products for researchers. Today, the center remains locally focused, serving community hospitals, patients and donors, while contributing to research and advancement that impact the world at large. More information is available at stanfordbloodcenter.org.

    About Aditxt Therapeutics

    Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. The immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit www.aditxt.com.

    Forward-Looking Statements

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Forward looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product development; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled "Risk Factors" in the Company's prospectus, dated June 29, 2020, that was filed with the U.S. Securities and Exchange Commission under File No. 333-235933, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the U.S. Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

    Contacts

    Investor Relations:



    PCG Advisory:

    Jeff Ramson

    Chief Executive Officer

    646-762-4518

     

    www.aditxt.com
    Media Relations:



    Stanford Blood Center

    Ross Coyle

    Public Relations Officer

    650-421-1993



    stanfordbloodcenter.org

    Primary Logo

    View Full Article Hide Full Article
  2. LOMA LINDA, CA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Aditx Therapeutics, Inc. (Aditxt) (the "Company") (NASDAQ:ADTX), a life sciences company developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced that it has appointed Jeff Ramson as Senior Advisor, Capital Markets and Communications.

    Mr. Ramson will advise, coordinate, and assist in the implementation of Aditxt's overall communications strategy with the capital markets and shareholders. He is a well-regarded business entrepreneur and innovator, with a proven track record of more than 25 years' experience on Wall Street, raising capital and providing strategic guidance for emerging…

    LOMA LINDA, CA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Aditx Therapeutics, Inc. (Aditxt) (the "Company") (NASDAQ:ADTX), a life sciences company developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced that it has appointed Jeff Ramson as Senior Advisor, Capital Markets and Communications.

    Mr. Ramson will advise, coordinate, and assist in the implementation of Aditxt's overall communications strategy with the capital markets and shareholders. He is a well-regarded business entrepreneur and innovator, with a proven track record of more than 25 years' experience on Wall Street, raising capital and providing strategic guidance for emerging public and private companies in various stages of development. As Chief Executive Officer of PCG Advisory, Inc., a leading investor relations and digital strategies firm which he founded in 2008, Jeff has been a pioneer in the intelligent use of social media to advance investor relations goals and increase awareness among key stakeholders. 

    Amro Albanna, Co-founder and Chief Executive Officer of Aditxt, stated, "I have worked closely with Jeff over the last few years during the evolution of Aditxt from a private company through the recent completion of our NASDAQ IPO. Jeff's collective experience in capital markets, investor relations, and digital communications, ideally positions him to implement our vision of engaging the capital markets and stakeholders into our mission. 

    Jeff Ramson added, "I have had the good fortune to work side by side with Amro over the last two and a half years.  His dedication and commitment to execute on behalf of Aditxt are unparalleled. We share the vision that building a large and diverse community of engaged stakeholders is a foundation for building a large community of quality, long-term investors. Aditxt has put together a world-class team and I very much look forward to contributing to the Company's path to success." 

    About Aditx Therapeutics

    Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. The immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit, www.aditxt.com

    Forward-Looking Statements

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Forward-looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product development; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled "Risk Factors" in the Company's prospectus, dated June 29, 2020, that was filed with the U.S. Securities and Exchange Commission under File No. 333-235933, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the U.S. Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

    Investor Relations:

    PCG Advisory:

    Jeff Ramson

    Chief Executive Officer



    646-762-4518

    www.aditxt.com

    Primary Logo

    View Full Article Hide Full Article
  3. Ms. Anthony and Her Legal Team have Represented Private and Public Finance Transactions in excess of $1 Billion

    Loma Linda, CA, July 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (NASDAQ:ADTX), a life sciences company developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced that it has appointed Laura Anthony to the Company's Board of Directors, effective as of July 2, 2020.

    Ms. Anthony will be an independent director in accordance with the applicable rules of the Nasdaq Stock Market LLC. She will serve as the Chair of the Corporate Governance Committee and will serve on the Audit and Compensation…

    Ms. Anthony and Her Legal Team have Represented Private and Public Finance Transactions in excess of $1 Billion

    Loma Linda, CA, July 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (NASDAQ:ADTX), a life sciences company developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced that it has appointed Laura Anthony to the Company's Board of Directors, effective as of July 2, 2020.

    Ms. Anthony will be an independent director in accordance with the applicable rules of the Nasdaq Stock Market LLC. She will serve as the Chair of the Corporate Governance Committee and will serve on the Audit and Compensation Committee as well.

    Amro Albanna, Co-founder and Chief Executive Officer of Aditxt, commented, "On behalf of the Board, we're pleased to welcome Laura to Aditxt's Board of Directors. We believe that the high regard of her legal expertise, including extensive experience as corporate counsel to both private and public companies, will benefit Aditxt as we work to execute and advance our strategic plans. We look forward to working with Laura and her contribution to our growth and development."

    Ms. Anthony is the founding partner of Anthony L.G., PLLC, a corporate, securities and business transactions law firm and has been practicing law since 1993. Ms. Anthony provides corporate counsel to small-cap and middle market private and public companies.  For over twenty-five years, Ms. Anthony has served clients in the areas of compliance with the Securities Act of 1933, including private and public offerings; NASDAQ and NYSE initial and continued listing requirements; registration and reporting requirements under the Securities Exchange Act of 1934; initial public offerings, follow-on offerings and mergers and acquisitions; and general contract and business transactions. Ms. Anthony received a juris doctorate from Florida State University College of Law in 1993.

    About Aditx Therapeutics

    Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. The immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com

    Forward-Looking Statements

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, including the Company's expectations regarding the proposed offering of the Company's shares of common stock, including as to the consummation of the offering described above and the size of the offering are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission, including, but not limited to, risk factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

    Contacts

    Investor Relations:

    PCG Advisory:

    Jeff Ramson

    Chief Executive Officer



    646-762-4518

    www.aditxt.com

    Primary Logo

    View Full Article Hide Full Article
  4. Ms. Pankovcin has 30 Years of Public Company Financial Experience with World Class Organizations

    LOMA LINDA, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), a life sciences company developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced that it has appointed Corinne Pankovcin as Chief Financial Officer, effective as of July 2, 2020.

    "Corinne Pankovcin is a skilled financial executive with 30 years of public company financial experience. Her reputation for building strong relationships with key stakeholders, combined with her in depth knowledge of the requirements…

    Ms. Pankovcin has 30 Years of Public Company Financial Experience with World Class Organizations

    LOMA LINDA, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), a life sciences company developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced that it has appointed Corinne Pankovcin as Chief Financial Officer, effective as of July 2, 2020.

    "Corinne Pankovcin is a skilled financial executive with 30 years of public company financial experience. Her reputation for building strong relationships with key stakeholders, combined with her in depth knowledge of the requirements of SEC regulated public companies, will be of great benefit to Aditxt as we continue to grow the company and execute on our strategic plans. We welcome Corinne to the Aditxt team and look forward to her contributions to our growth," said Amro Albanna, Co-founder and Chief Executive Officer of Aditxt.

    Prior to joining Aditxt, Ms. Pankovcin was the Chief Financial Officer and Managing Director of Business Development Corporation of America ("BDCA"), a business development company, from December 2015 to July 2019. At BDCA, Ms. Pankovcin was responsible for strategic planning, financial forecasting, and financial reporting, in addition to being a trusted advisor and resource to BDCA leadership.  From January 2011 to August 2015, Ms. Pankovcin was the Chief Financial Officer and Treasurer of BlackRock Capital Investment Corporation, and a Managing Director of Finance at BlackRock Investment Management LLC. Prior to joining BlackRock, Ms. Pankovcin was a senior member of Finance & Accounting of Alternative Investments and served as Chief Financial Officer for the Global Emerging Markets products group at AIG Capital Partners. Ms. Pankovcin began her career with PricewaterhouseCoopers LLP, where she ultimately held the role of Senior Manager of Business Assurance for Consumer Products, Manufacturing, and Middle Market industries from 1991 to 2001.

    Ms. Pankovcin earned a Bachelor of Science degree in Accounting from Dowling College and a Master of Business Administration from Hofstra University. She is a Certified Public Accountant.

    About Aditx Therapeutics

    Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. The immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com

    Forward-Looking Statements

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, including the Company's expectations regarding the proposed offering of the Company's shares of common stock, including as to the consummation of the offering described above and the size of the offering are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission, including, but not limited to, risk factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

    Investor Relations Contact:

    PCG Advisory:

    Jeff Ramson

    Chief Executive Officer



    646-762-4518

    www.aditxt.com

    Primary Logo

    View Full Article Hide Full Article
  5. LOS ANGELES, CA / ACCESSWIRE / July 16, 2020 / LD Micro today announced that it will be hosting ten companies over the final two weeks of July, with a group presentation in the morning, followed by private investor meetings throughout the day.

    "Let's be real. COVID has hampered everything on the physical conference side, unless you are an N95 mask manufacturer, stated Chris Lahiji, president of LD Micro. He continued, "with that being said, we are not letting it get in the way of what we do best; connecting analysts and investors to micro-cap companies. The level of demand that we are seeing on both sides is remarkable. The LD Micro platform is suited for all mediums, including ‘zooming,' because of the size, scope, and influence of our large…

    LOS ANGELES, CA / ACCESSWIRE / July 16, 2020 / LD Micro today announced that it will be hosting ten companies over the final two weeks of July, with a group presentation in the morning, followed by private investor meetings throughout the day.

    "Let's be real. COVID has hampered everything on the physical conference side, unless you are an N95 mask manufacturer, stated Chris Lahiji, president of LD Micro. He continued, "with that being said, we are not letting it get in the way of what we do best; connecting analysts and investors to micro-cap companies. The level of demand that we are seeing on both sides is remarkable. The LD Micro platform is suited for all mediums, including ‘zooming,' because of the size, scope, and influence of our large community. This will be a solid ramp-up to our LD 500 in September, and we can't wait to begin."

    To register for presentations, click the company name below:

    7/20 8am PT Kindred Bio (KIN)
    7/21 8am PT electroCore (ECOR)
    7/22 8am PT Aspen Group(ASPU)
    7/23 8am PT Nephros (NEPH)
    7/24 9am PT Recruiter.com Group (RCRT)
    7/27 8am PT BioSig Technologies(BSGM)
    7/28 8am PT ADiTx Therapeutics (ADTX)
    7/29 8am PT Exro Tech (EXROF)
    7/30 8am PT VolitionRx(VNRX)
    7/31 8am PT Lantern Pharma (LTRN)

    About LD Micro

    LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space.

    What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event).

    In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.

    For those with any questions, please contact David Scher at or visit www.ldmicro.com for more information.

    SOURCE: LD Micro



    View source version on accesswire.com:
    https://www.accesswire.com/597639/Zooming-with-LD-to-Feature-10-Distinct-Companies-July-20th-31st

    View Full Article Hide Full Article
View All ADiTx Therapeutics Inc. News